RBR-88bjcv招募中2 期
Randomized, controlled study of complement inhibition in the treatment of SARS-Cov-2 pneumonia COMPVID STUDY - -:
Hospital Eduardo de Menezes0 个研究点开始时间: 2020年11月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 80Y（—）
入选标准
- •Be between 18 and 80 years old; weight between 50 and 100 kg; maximum of 10 days of symptoms; admission to the intensive care unit or COVID-19 unit with suspected COVID-19 pneumonia and 93% less oxygen saturation in room air, but not receiving mechanical ventilation; diagnosis of COVID-19 infection based on a viral polymerase chain reaction test, rapid test or based on symptoms associated with a consistent lung tomography; be able to provide a free consent form or have the free consent form provided by a legally designated representative.
排除标准
- •Patients who received treatment with inhibitors of complement system factors (such as eculizumab) or treatments with therapy with biological immunomodulators (example tocilizumab, etanercept, infliximab) in the 4 weeks prior to the admission in the study; patients involved in other clinical studies; patients with active tissue or systemic bacterial or fungal infection; pregnant or breastfed patients; patients with more than ten days of symptoms.
研究者
相似试验
尚未招募
不适用
Identification of complement inhibitors and complement regulatory proteins in ABO-incompatible compare with HLA-incompatible kidney transplantatioABOi kidney transplantationHLAi kidney transplantationAccommodationABO incompatibility or ABO incompatible kidney transplantationComplement regulatory proteinsComplement inhibitorsHLA incompatibility or HLA incompatible kidney transplantationKidney transplantationTCTR20210904002/A30
进行中（未招募）
1 期
ICA-GBSGuillain-Barré SyndromeMedDRA version: 14.1Level: LLTClassification code 10018766Term: Guillain Barre syndromeSystem Organ Class: 100000004852EUCTR2013-000228-33-GBHS Greater Glasgow & Clyde
招募中
不适用
Open-label, randomized study of inhibitory effect of evogliptin, the dipeptidyl peptidase-4 inhibitor, on the progression of aortic valve calcification in patients with type 2 diabetes mellitus and mild-to-moderate aortic stenosisKCT0005375Asan Medical Center160
招募中
2 期
Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury ( A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management of severe traumatic brain injury)NL-OMON52831eids Universitair Medisch Centrum106
尚未招募
2 期
CIAO@TBI2024-514488-24-02Leids Universitair Medisch Centrum (LUMC)106